SYC also said that ALL of PTX's assets were winning.That Cell...

SYC also said that ALL of PTX's assets were winning.
That Cell Pryme M is ready now to go into the clinic with only a minor amendment to manufacturing details of their product needed by a 3rd party. Likely most keen first buyers would be CAR T developers who are right now only getting mediocre results with their product so far. Cell Pryme M doubles the % of helpful T cells, cells lasts longer (can last for decades) and find the tumour better. He also said that all patients who have received CAR-T over the past 10 years and are in complete/?cure or partial remission have one common factor: they all have a very high % of these Memory and Central Memory T cells.
Interestingly Cellpryme M also creates a significant increase in antiviral activity. Nothing planned on that yet.